article
24.07.2019

Rituximab biosimilar as first-line treatment for diffuse large B-cell lymphoma

Another project from our portfolio for mAbxience, where OCT Clinical Trials was responsible for all activities in Russia, including site selection, project management, data management, clinical and medical monitoring, final report preparation, logistics:

Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. Read the full article here.